|
Glioblastoma
|
|
|
|
|
de Groot JF, Gilbert MR, Aldape K, Hess KR,
Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V,
Yung WK
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in
patients with recurrent glioblastoma
J Neurooncol. 2008 Jun 26; [Epub ahead of print]
 Abstract |
DBLinks | 
BL 7:13
|
|
T. Cloughesy, A. Yung,
J. Vrendenberg, K. Aldape, D. Eberhard,
M. Prados, S. Vandenberg, B. Klencke
and P. Mischel
Phase II study of erlotinib in recurrent GBM: Molecular predictors of
outcome
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1507.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1507
|
|
S. Krishnan, P.
Brown, K. Ballman, J. Fiveash, J.
Uhm, C. Giannini, F. Geoffroy, L.
Nabors and J. Buckner
Phase I trial of erlotinib with
radiation therapy (RT) in patients with glioblastoma multiforme (GBM)
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1513.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005:
1513
|
|
M. A. Vogelbaum, D. Peereboom, G.
Stevens, G. Barnett, C. Brewer
Phase II trial of the EGFR tyrosine kinase
inhibitor erlotinib for single agent therapy of recurrent Glioblastoma
Multiforme: Interim results
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1558
|
|
A. Yung, J. Vredenburgh, T.
Cloughesy, B. J. Klencke, P. S. Mischel, D. D. Bigner, K. Aldape, S. Vanderburg,
M. Prados, The Accelerate Brain Cancer Cure Group
Erlotinib HCL for glioblastoma multiforme in first
relapse, a phase II trial
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1555
|
|
|
Gliomas
|
|
|
|
|
Brandes AA, Franceschi E, Tosoni A, Hegi ME,
Stupp R
Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and
disappointments
Clin
Cancer Res. 2008 Feb 15;14(4):957-60
Abstract |
DBLinks | BL 7:12
|
|
Lassman AB, Rossi MR, Razier JR, Abrey LE,
Lieberman FS, Grefe CN, Lamborn K, Pao W, Shih AH, Kuhn JG, Wilson R, Nowak NJ,
Cowell JK, Deangelis LM, Wen P, Gilbert MR, Chang S, Yung WA, Prados M, Holland
EC
Molecular study of malignant
gliomas treated with epidermal growth factor receptor inhibitors: tissue
analysis from north american brain tumor consortium trials 01-03 and 00-01
Clin
Cancer Res. 2005 Nov 1;11(21):7841-50
|
|
M.
Prados, S. Chang, E. Burton, A. Kapadia, J. Rabbitt, M. Page, A. Federoff,
S. Kelly, G. Fyfe
Phase I study of OSI-774 alone or with temozolomide in
patients with malignant glioma
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No. 394
|
|
J. J. Raizer, L. E. Abrey, P. Wen,
T. Cloughesy, I. A. Robins, H. A. Fine, F. Lieberman, V. K. Puduvalli, K. L.
Fink, M. Prados
A phase II trial of erlotinib (OSI-774) in patients
(pts) with recurrent malignant gliomas (MG) not on EIAEDs
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1502
|
|
|
Hemangioblastoma
|
|
|
|
Lisa
R Rogers, William Kaelin, Paul Nadler, Anthony F Shields, Patricia LoRusso
Response
of cerebellar hemangioblastomas associated with von Hippel-Lindau disease to
OSI-774 (TarcevaTM)
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No.
2111
|
|
|
Metastatic
Tumors |
|
|
|
|
Altavilla G, Arrigo C, Santarpia MC, Galletti G,
Picone G, Marabello G, Tomasello C, Pitini VV
Erlotinib therapy in a patient with non-small-cell lung cancer and brain
metastases
J Neurooncol.
2008 Jun 20. [Epub ahead of print]
Abstract |
DBLinks |
BL 7:14
|
|
|
Costa DB, Kobayashi S
Response of intracranial metastases to epidermal growth factor receptor
tyrosine kinase inhibitors: it may all depend on EGFR mutations
J
Clin Oncol. 2008 Feb 1;26(4):686.
Abstract |
 Full Text |
 Reprint |
DBLinks | BL 7:6
|
|
|
Fekrazad MH, Ravindranathan M, Jones DV Jr.
Response of intracranial metastases to erlotinib therapy
J
Clin Oncol. 2007 Nov 1;25(31):5024-6
Abstract |
Full Text |
Reprint |
DBLinks | BL 7:6
|
|
|
|
